# ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma

> **NCT03337919** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University College, London** · enrollment: 78 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03337919
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-03
- **Primary completion:** 2023-03-01
- **Final completion:** 2026-02-28
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2024-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03337919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03337919, "ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03337919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*